Hematological Questions in Personalized Management of COVID-19 Vaccination

Wu, Tingting; Li, Junying; Hu, Yu; Tang, Liang

doi:10.3390/jpm13020259

Cited by 2 publications

(1 citation statement)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been causing a worldwide pandemic since 2019. 1 The clinical manifestations of COVID-19 infection are complex and diverse, and the whole systems may be affected, including the skin. Vitiligo is an acquired chronic depigmenting disorder of the skin resulting from selective destruction of melanocytes, and autoimmune abnormality is one of the main causes of vitiligo.…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 Vaccine and COVID-19 Infection on Vitiligo Activity and Progression

Shi,

Sun,

Ding

2023

CCID

View full text Add to dashboard Cite

Background Coronavirus disease 2019 (COVID-19) has given rise to several new onset or exacerbated dermatologic disorders including vitiligo. However, the relationship between COVID-19 infection or its associated vaccines and vitiligo progression is unclear. Aim We investigate the impact of COVID-19 infection and its associated vaccines on vitiligo progression. Methods A cross-sectional study was performed among patients who visited Department of Dermatology, Peking University People’s Hospital between 2022.1 and 2023.6. Detailed information including demographic characteristics, vitiligo clinical features, information on COVID-19 infection and vaccination and disease progression was collected by an electronic questionnaire. Results Overall, 314 patients with vitiligo completed the questionnaire. 47.5% were males, with an average age of 25.5±15.9 years. 266 (84.7%) patients had received COVID-19 vaccination, and 70.3% of the patients reported progression of vitiligo after vaccination, mostly within 3 months. 55.6% of the patients had disease progression after the second dose of vaccine. 270 patients experienced COVID-19 infection, and 30.7% of these patients had progression of vitiligo after infection, most of the progression occurred within 1–2 months. 184 patients (68.2%) interrupted treatment. Analysis results indicated patients in active stage had a higher risk for vitiligo progression after COVID-19 infection and vaccination.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 Vaccine and COVID-19 Infection on Vitiligo Activity and Progression

Shi,

Sun,

Ding

2023

CCID

View full text Add to dashboard Cite

show abstract

Myocardial Infarction Following Vaccination Against COVID-19: A Systematic Review

Rahimi Petrudi,

Abdollahi,

Mirzaii-Dizgah

2023

Ann Mil Health Sci Res

View full text Add to dashboard Cite

Context: Several reports have been presented regarding the occurrence of acute myocardial infarction following vaccination against COVID-19. Objectives: The current systemic review tried to review and summarize the published evidence and documents regarding the occurrence of myocardial infarction following various types of anti-COVID-19 vaccines (AstraZeneca and Pfizer) and, finally, take steps to clarify the causes of such incidents. Methods: The relevant databases, including Medline, Web of Knowledge, Google Scholar, Scopus, and Cochrane, were comprehensively searched by the two blinded researchers for all eligible studies based on the considered keywords. Of 76 articles initially collected by database searching, 20 articles were included in the last analysis. Results: The occurrence of acute myocardial infarction was mostly related to SARS-CoV-2-based messenger RNA and viral vector vaccines. This cardiac attack occurred after the first vaccination in 74% of patients affected. The time of occurrence of myocardial infarction was also very different between different types of vaccines and varied between 15 minutes and 21 days after vaccination. Most of the myocardial infarctions that occurred after vaccination were of the ST-segment elevation type (STEMI) (23 of 28 patients). More than two-thirds of myocardial infarction cases occurred in patients who had significant cardiovascular risk profiles (hypertension, diabetes mellitus, and ischemic heart disease). Overall, 22.2% of cases suffering post-vaccination myocardial infarction died within hospitalization. Conclusions: The occurrence of myocardial infarction following the vaccination against COVID-19 is rare, and due to the fatality of this event, it is necessary to modify the biotechnological production of existing vaccines and to accurately evaluate the pathophysiology of this event.

show abstract

Hematological Questions in Personalized Management of COVID-19 Vaccination

Cited by 2 publications

References 67 publications

Impact of COVID-19 Vaccine and COVID-19 Infection on Vitiligo Activity and Progression

Impact of COVID-19 Vaccine and COVID-19 Infection on Vitiligo Activity and Progression

Myocardial Infarction Following Vaccination Against COVID-19: A Systematic Review

Contact Info

Product

Resources

About